ACIP Recommendations: COVID-19 Vaccine

Published in Morbidity and Mortality Weekly Report (MMWR)

The Advisory Committee on Immunization Practices (ACIP) provides advice and guidance to the Director of the CDC regarding use of vaccines and related agents for control of vaccine-preventable diseases in the civilian population of the United States. Recommendations made by the ACIP are reviewed by the CDC Director and, if adopted, are published as official CDC/HHS recommendations in the Morbidity and Mortality Weekly Report (MMWR).

CURRENT COVID-19 Vaccine Recommendations

• MMWR, September 10, 2024. Vol 73 (37);819-824. Use of COVID-19 Vaccines for Persons Aged ≥6 Months: Recommendations of the Advisory Committee on Immunization Practices — United States, 2024–2025.
  

ARCHIVED COVID-19 Immunization Publications

For your convenience, these archived publications can be used for historical and research purposes.

• MMWR, April 25, 2024, Vol 73(16);377-381
  Use of an Additional Updated 2023–2024 COVID-19 Vaccine Dose for Adults Aged ≥65 Years: Recommendations of the Advisory Committee on Immunization Practices — United States, 2024
  • Print version
  • See also:
    • ACIP Evidence to Recommendations (EtR) for Use of an Additional Dose of Updated (2023-2024 Formula) COVID-19 Vaccine in Older Adults | CDC

• MMWR, October 20, 2023, Vol 72(42);1140–1146
  Use of Updated COVID-19 Vaccines 2023–2024 Formula for Persons Aged ≥6 Months: Recommendations of the Advisory Committee on Immunization Practices — United States, September 2023
  • Print version
  • See also:
    • Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): Updated COVID-19 vaccine (2023-2024 Formulation) | CDC
    • EtR framework for Use of an Updated (Monovalent XBB Containing) COVID-19 Vaccine Under an Emergency Use Authorization | CDC

• MMWR, June 16, 2023, Vol 72(24);657–662
  Interim Recommendations for Use of Bivalent mRNA COVID-19 Vaccines for Persons Aged ≥6 Months — United States, April 2023
  • Print version
• MMWR, November 11, 2022, Vol 71(45); 1436-1441
  Interim Recommendations from the Advisory Committee on Immunization Practices for the Use of Bivalent Booster Doses of COVID-19 Vaccines — United States, October 2022 | MMWR (cdc.gov)
  • Print version
  • See also:
    • ACIP Evidence to Recommendations (EtR) for Use of Bivalent COVID-19 Vaccine Booster Doses under an Emergency Use Authorization | CDC
    • ACIP Evidence to Recommendations (EtR) for Use of Novavax COVID-19 Vaccine Booster Dose for adults ages 18 years and older under an Emergency Use Authorization | CDC
• MMWR, August 4, 2022, Vol 71(31); 988-992
  Interim Recommendation of the Advisory Committee on Immunization Practices for use of the Novavax COVID-19 vaccine in persons aged 18 years and older— United States, July 2022
  • Print version
  • See also:
    • Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): Novavax COVID-19 Vaccine (cdc.gov)
    • ACIP Evidence to Recommendations for Use of Novavax COVID-19 Vaccine, Adjuvanted in adults ages 18 years and older under an Emergency Use Authorization (cdc.gov)
    • The Novavax COVID-19 Vaccine's Local Reactions, Systemic Reactions, Adverse Events, and Serious Adverse Events (cdc.gov)
      
• Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): Moderna COVID-19 Vaccine for Children Aged 6–11 Years
• Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): Moderna COVID-19 Vaccine for Persons Aged 12-17 Years
• ACIP Evidence to Recommendations for Use of Moderna COVID-19 Vaccine in Children Ages 6 – 11 years and Adolescents Ages 12 – 17 years under an Emergency Use Authorization
• MMWR, June 28, 2022, Vol 71(26);859–868
  Interim Recommendations of the Advisory Committee on Immunization Practices for Use of Moderna and Pfizer-BioNTech COVID-19 Vaccines in Children Aged 6 Months–5 Years — United States, June 2022
  • Print version
  • See also:
    • GRADE: Moderna COVID-19 Vaccine for Children Aged 6 Months–5 Years | CDC
    • GRADE: Pfizer-BioNTech COVID-19 Vaccine for Children Aged 6 Months–4 Years | CDC
    • ACIP Evidence to Recommendations for Use of Moderna COVID-19 Vaccine in Children Ages 6 Months – 5 Years and Pfizer-BioNTech COVID-19 Vaccine in Children Ages 6 Months – 4 Years under an Emergency Use Authorization | CDC
    • Moderna COVID-19 Vaccine's Reactions and Adverse Events | CDC
    • Pfizer-BioNTech COVID-19 Vaccine Reactions & Adverse Events | CDC
• EtR Update for a Pfizer-BioNTech COVID-19 Booster in Children Ages 5-11 Years
• EtR Framework for a 2nd COVID-19 Booster Dose in Adults Ages 50 Years and Older and Immunocompromised Individuals
• MMWR, March 18, 2022, Vol 71(11);416–421
  Use of Moderna COVID-19 Vaccine in Persons Aged ≥18 Years and Considerations for Extended Intervals for Administration of Primary Series Doses of mRNA COVID-19 Vaccines — United States, February 2022
  • Print version
  • See also:
    • Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): Moderna COVID-19 Vaccine | CDC
    • ACIP Evidence to Recommendations for Use of Moderna COVID-19 Vaccine | CDC
• MMWR, January 21, 2022, Vol 71(3);90–95
  Use of the Janssen (Johnson & Johnson) COVID-19 Vaccine: Updated Interim Recommendations from the Advisory Committee on Immunization Practices – United States, December 2021
  • Print version
• MMWR, November 5, 2021, Vol 70(45);1579–1583
  Use of Pfizer-BioNTech COVID-19 Vaccine in Children Aged 5–11 Years — United States, November 2021
  • Print version
• MMWR, November 5, 2021, Vol 70(44);1545–1552
  Interim Recommendations for Additional Primary and Booster Doses of COVID-19 Vaccines — United States, 2021
  • Print version
  • See also:
    • Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): Pfizer-BioNTech, Moderna, and Janssen COVID-19 booster doses
    • ACIP Evidence to Recommendations for Use of an Additional COVID-19 Vaccine Dose in Immunocompromised People
    • ACIP Evidence to Recommendations for Use of COVID-19 Vaccine Booster Doses
      
• MMWR, September 24, 2021, Vol 70(38);1344–1348
  Use of Pfizer-BioNTech COVID-19 Vaccine in Persons Aged ≥16 Years: Recommendations of the Advisory Committee on Immunization Practices — United States, September 2021
  • Print version
  • See also:
    • Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): Pfizer-BioNTech COVID-19 Vaccine
    • ACIP Evidence to Recommendations for Use of Pfizer-BioNTech COVID-19 Vaccine
• MMWR, August 13, 2021, Vol 70(32);1094-1099
  Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices — United States, July 2021
  • Print version
• MMWR, July 9, 2021, Vol 70(27);977–982
  Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices — United States, June 2021
  • Print version
• MMWR, May 14, 2021, Vol 70(20);749–752
  The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine in Adolescents Aged 12–15 Years — United States, May 2021
  • Print version
  • See also:
    • Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): Pfizer-BioNTech COVID-19 Vaccine for Persons Aged 12-15 Years
    • ACIP Evidence to Recommendations for Use of Pfizer-BioNTech COVID-19 Vaccine under an Emergency Use Authorization
    • Local Reactions, Systemic Reactions, Adverse Events, and Serious Adverse Events: Pfizer-BioNTech COVID-19 Vaccine
• MMWR, April 30, 2021, Vol 70(17);651-656
  Updated Recommendations from the Advisory Committee on Immunization Practices for Use of the Janssen (Johnson & Johnson) COVID-19 Vaccine After Reports of Thrombosis with Thrombocytopenia Syndrome Among Vaccine Recipients — United States, April 2021
  • Print version
  • See also:
    • Risk-Benefit Analysis
• MMWR, March 2, 2021, Vol 70(9);329–332
  The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Janssen COVID-19 Vaccine — United States, February 2021
  • Print version
  • See also:
    • ACIP Evidence to Recommendations for Use of Janssen COVID-19 Vaccine under an Emergency Use Authorization
    • Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): Janssen COVID-19 Vaccine
    • Local Reactions, Systemic Reactions, Adverse Events, and Serious Adverse Events: Janssen COVID-19 Vaccine
• MMWR, December 22, 2020, Vol 69(5152);1657-1660
  The Advisory Committee on Immunization Practices' Updated Interim Recommendation for Allocation of COVID-19 Vaccine — United States, December 2020
  • Print version
  • See also:
    • Evidence Table for COVID-19 Vaccines Allocation in Phases 1b and 1c of the Vaccination Program
• MMWR, December 20, 2020, Vol 69(5152);1653-1656
  The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Moderna COVID-19 Vaccine — United States, December 2020
  • Print version
  • See also:
    • Evidence to Recommendations
    • GRADE Evidence Tables
    • Local Reactions, Systemic Reactions, Adverse Events, and Serious Adverse Events
• MMWR, December 13, 2020, Vol 69(50);1922-1924
  The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine — United States, December 2020
  • Print version
  • See also:
    • Local Reactions, Systemic Reactions, Adverse Events, and Serious Adverse Events
    • Interim Considerations: Preparing for the Potential Management of Anaphylaxis at COVID-19 Vaccination Sites
• MMWR, December 3, 2020, Vol 69(49);1857-1859
  The Advisory Committee on Immunization Practices' Interim Recommendation for Allocating Initial Supplies of COVID-19 Vaccine — United States, 2020
  • Print version
  • See also:
    • Evidence Table